Injectable Systems for Long-lasting Insulin Therapy

Adv Drug Deliv Rev. 2023 Oct 26:115121. doi: 10.1016/j.addr.2023.115121. Online ahead of print.ABSTRACTInsulin therapy is the mainstay to treat diabetes charactered by hyperglycemia. However, its short half-life of only 4-6 min limits its effectiveness in treating chronic diabetes. Advances in recombinant DNA technology and protein engineering have led to several insulin analogue products that have up to 42 h of glycemic control. However, these insulin analogues still require once- or twice-daily injections for optimal glycemic control and have poor patient compliance and adherence issues. To achieve insulin release for more than one day, different injectable delivery systems including microspheres, in situ forming depots, nanoparticles and composite systems have been developed. Several of these delivery systems have advanced to clinical trials for once-weekly insulin injection. This review comprehensively summarizes the developments of injectable insulin analogue and delivery systems covering the whole field of injectable long-lasting insulin technologies from prototype design, preclinical studies, clinical trials to marketed products for the treatment of diabetes.PMID:37898336 | DOI:10.1016/j.addr.2023.115121
Source: Advanced Drug Delivery Reviews - Category: Drugs & Pharmacology Authors: Source Type: research